stockrow
Friday 6 November 2026
Export XENE’s income statement to Excel — free account
Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
39.00
1.32
+3.50%
Follow XENE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
20.71 | 27.53 | 13.17 | 12.08 | |
Current Ratio |
21.02 | 27.79 | 13.42 | 12.52 | |
Net Debt/EBITDA |
7.59 | 9.80 | 5.03 | 4.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 0.87 | 0.77 | 0.79 | |
Capex/Depreciation |
(0.49) | (0.23) | (0.52) | (0.44) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.96) | (1.02) | (1.03) | (0.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.96) | (1.02) | (1.03) | (0.91) | |
Cash per Share |
9.34 | 12.53 | 6.93 | 5.83 | |
Shareholders Equity per Share |
12.47 | 15.32 | 7.34 | 7.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.47 | 15.32 | 7.34 | 7.06 | |
Free Cash Flow |
(95.66) | (89.03) | (81.80) | (72.03) | |
Working Capital |
900.86 | 1,066.82 | 518.86 | 441.80 | |
Capital Expenditures |
(0.27) | (0.13) | (0.32) | (0.28) | |
Net Current Asset Value |
892.49 | 1,057.64 | 509.25 | 431.81 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.36 | 4.91 | 1.42 | 0.88 | |
Average Payables |
37.63 | 34.45 | 37.24 | 32.57 | |
Average Assets |
985.03 | 1,065.05 | 715.65 | 721.87 | |
Average Common Equity |
938.19 | 1,020.89 | 668.33 | 678.66 |
Columns are period end dates